


### ASSOCIATION BETWEEN FBN1 POLYMORPHISMS AND TGF- ß1 CONCENTRATION WITHIN ANEURYSMS AND DISSECTIONS OF ASCENDING THORACIC AORTA




**Ramune Sepetiene** 

Laboratory of Molecular Cardiology, Institute of Cardiology , Medicine Academy, LUHS

26-27 October, Chicago

A high mortality is determined by Dilatative Pathology of Ascending Aorta (DPAA). **15 000** people die every year due to the complications of DPAA in USA.

DPAA takes **14th** place according to the reasons of mortality among 55 years people and older (National Centre of Health Statistics in USA, 2012)




### DPAA is diagnosed **5,9 : 100 000 worldwide**

(Anderson CA et al. Ascending aortic aneurysms. Cardiac surgery in adult. New York: McGraw-Hill; 2009; 1123-1148)

### Morbidity by DPAA in Lithuania

(cases per/100 000 population)



#### ICD-10 Version:2016 - World HealthOrganization

I71.01 – Dissection of Thoracic Aorta

171.1 – Aneurysm of Thoracic Aorta, dissected

I71.2 – Aneurysm of Thoracic Aorta, dissection not indicated Data from Health Information Centre at Lithuanian Hygiene Institute, 2014


# Morphogenesis of aneurysm


 A contractive phenotype of smooth muscle cells, responsable for vascular resistance, to be conversed to synthetic phenotype.

(Lesauskaite et al "Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors." *Human pathology* 32.9 (2001): 1003-1011)

 Primary remodeling of pathological structural proteins: collagen and elastin, with extracellular proteases involved


Aortic media





### Aortic dissection

Lesauskaite V, Dilatative pathology of ascending aorta, a new attitude, Oral presentation , 2012.



#### Mutations of Fibrillin-1gene

Elevated concentration of TGF- β1 in blood is found for patients with diagnose of Marfan syndrome (MFS), determined by mutations of *Fibrillin-1 (FBN1) gene*.

Milewicz DM, Michael K, Fisher N, Coselli JS, MarkelloT and Biddinger A. (1996) Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. *Circulation* 94:2708-2711

Chaudhry SS, et al (2007) Fibrillin-1 regulates the bioavailability of TGF $\beta$ 1. J Cell Biol. 176:355-367 .



El Greco (Domenikos Theotokopoulos) (1541–1614)




### <u>The Great Virtuoso</u> <u>Violinists/Composers of the</u> <u>18th Century: Nicola Paganini</u>

It is now thought that Paganini's genetic condition was <u>Marfan Syndrome</u>, which would explain his bouts of ill health, especially in his later life. Paganini suffered with joint pain, poor vision, breathlessness, chest pains and fatigue. These less desirable symptoms meant that he frequently had to cancel public performances and he died at the relatively young age of 58. It's established already, that *FBN1* SNP's (rs2118181, rs1059177) even did not cause MFS, but are significantly associated with DPAA formation.


LeMaire SA et al (2011) Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21. 1. Nat Genet. 43:996-1000


With changes in FBN1 protein, TGF-beta1 concentration of active form becomes elevated in blood

Milewicz DM, Michael K, Fisher N, Coselli JS, MarkelloT and Biddinger A. (1996) Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. *Circulation* 94:2708-2711



#### Interaction of FBN1 and TGFß1 mechanisms in molecular level





# A purpose of the research

## To chech a hypothesis-

does the correlation between FBN1 SNP's (rs2118181, rs1059177) and sporadic DPAA formation exist with elevated concentration of TGF- beta1in blood plasma

#### **Materials and methods**


1. A sample of patients, operated due to the DPAA conditions, n = 312.

2. A sample of Reference group, **n=472**, consisted from random Lithuanian population, collected during epidemiologic studies.


3. A sample from random clusters, **n=269**, consisted from Kaunas city population, without complains of CVD, except AH.



Blood samples from *cubital vein* were collected in two tubes with EDTA conservating material. Blood plasma was separated and freezed at -20°C



Genomic DNA, extracted from blood, and genotyping analysis was carried out using the real-time polymerase chain reaction (method (7900HT Applied Biosystem, USA).




Plasma was obtained within 2 hours by spinning for 15 min at 2500 rpm, aliquoted and stored frozen at -20°C. Plasma samples were tested in duplicate using eBioscience Platinum (Bender Med Systems GmbH, Austria) human TGF-β1 ELISA kit based on standard sandwich enzyme-linked immune-sorbent assay technology according to manufacturers' instructions. Statistics done by SPSS package(version 16.0) with -non-parametric Kruskal-Wallis test,

-two-tailed Spearman's Rank Correlation coefficient(R). -Multiple linear regression was used to estimate the effect of gender (male), age (years), and genotype on the logarithmically transformed TGF- $\beta$ 1 values.



#### Distribution of samples between Reference group and Patients with DPAA according to the age and gender

	Aneurysms n = 160	Postenotic dilatation n = 79	Stanford A dissection n = 73	Total n=312	Reference group n = 472
<i>Age (years)</i> Median (range)	60 (18-83)	65 (27-81)	62 (24-84)	62 (18-84)	61 (25-83)
<i>Gender</i> Males, n (%)	135 (84.4)	57 (72.2)	54 (74.0)	246 (78.8)	372 (78.8)



#### **Genotyping results for subgroups tested (1)**

		Genotype frequency, n (%)		
Investigated group, n	Genotype	rs2118181	rs10519177	
Aneurysms n = 160 p	AA GA GG	112, (70.4) 42, (26.4) 5, (3.2) 0.019	83, (52.5) 61, (38.6) 14, (8.9) 0.254	
Postenotic dilatations n = 79 p	AA GA GG	56, (74.7) 17, (22.7) 2, (2.6) 0.362	47, (59.5) 26, (32.9) 6, (7.6) 0.657	
Stanford A dissections n = 73 p	AA GA GG	44, (60.3) 24, (32.9) 5, (6.8) <sup>+</sup> < <b>0.001</b>	28, (39.4) 29, (40.9) 14, (19.7) <sup>++</sup> < <b>0.001</b>	
Reference group n = 472	AA GA GG	378, (80.1) 89, (18.9) 5, (1.0)	272, (57.6) 174, (36.9) 26, (5.5)	

Lesauskaite V, Sepetiene R, Jariene G, Patamsyte V, Zukovas G *et al.* (2015) FBN1 polymorphisms in patients with the dilatative pathology of the ascending thoracic aorta. Eur J Cardiothorac Surg. 47:e124-30.

#### Genotyping results for subgroups tested (2)

SNP	Aneurysm	ls	Posten dilatati		Dissections (Stanford A)		Reference group	
	MAF	OR (CI, 95%)	MAF	OR (CI, 95%)	MAF	OR (CI, 95%)	MAF	OR (CI, 95%)
rs2118181	0.16	1.67 (1.61-2.40) p=0.005	0.14	1.39 (0.84-2.31) p=0.20	0.23	2.59 (1.67- 4.01) p<0.001	0.10	1.00 - -
rs10519177	0.28	1.25 (0.94-1.66) p=0.13	0.24	1.01 (0.68-1.49) p=0.98	0.40	2.13 (1.48- 3.08) p<0.001	0.24	1.00 - -

MAF-Minor alell frequency

OR- odd ratio


**CI-** Confidence interval

Lesauskaite V, Sepetiene R, Jariene G, Patamsyte V, Zukovas G *et al.* (2015) FBN1 polymorphisms in patients with the dilatative pathology of the ascending thoracic aorta. Eur J Cardiothorac Surg. 47:e124-30.

#### Concentration of TGF-β1 ng/ml for DPAA and Reference group

TGF-β1	Aneurysms n=35	Postenotic dilatation, n=21	Stanford A dissections, n=6	Total n=62	Reference group, n=212
Median	7.8	7.7	10.1	7.7	6.2
(range) ng/ml	(2.3-25.3)	(2.1-22.0)	(6.58-17.6)	(2.1-5.3)	(1.0-33.1)

Sepetiene, Ramune, et al. "Blood Plasma TGF-β1 Concentration in Sporadic Dilatative Pathology of Ascending Aorta: More Questions than Answers." *PloS one* 10.6 (2015): e0129353. TGFß-1 concentration in plasma for males (mediana 8,32 ng/ml) was significantly (p=0,001) different from females(mediana 5,81 ng/ml) and was growing up depending on age (p<0,001)



Age (23-87 years)

Sepetiene et al. "Blood Plasma TGF-β1 Concentration in Sporadic Dilatative Pathology of Ascending Aorta: More Questions than Answers." *PloS one* 10.6 (2015) e0129353.

# Association between *FBN1* SNPs genotypes and TGF-β1 concentration

FBN1 SNP	Genotype	TGF-β1	
genotype	frequency	concentration	People with rs2118181 AA genotype
	n (%)	(ng/ml)	had TGF-β1 concentration with median of 6,57 ng/ml,
		min/ med/ max	one minor allele <b>G</b> rised TGF- $\beta$ 1
rs2118181			median of concentration by 1,97
AA	198 (72.0)	1.00/ <b>6.57</b> / 33.12	ng/ml, <b>GG</b> genotype -3,21 ng/ml
AG	64 (23.3)	2.71/ <b>7.81</b> / 28.08 <sup>a</sup>	Higher TGF-β1 concentration
GG	13 (4.7)	1.40/ <b>9.78</b> / 17.28 <sup>b</sup>	median was detected for people with <b>rs10519177 GG</b> genotype,
rs10519177			comparing with <b>AA</b> genotype
AA	144 (52.4)	1.00/ <b>6.40</b> / 33.12 <sup>c</sup>	(10,48ng/ml and 6,40 ng/ml with p<0,0001,respectively).
AG	73 (26.5)	1.90/ <b>5.46</b> / 28.08 <sup>d</sup>	One <b>rs10519177</b> minor alelle <b>G</b> had no effect on TGF-β1 concentration.
GG	58 (21.1)	1.40/ <b>10.48</b> / 27.29	

a, TGF- $\beta$ 1 concentration, in compare rs2118181 AG and AA genotypes, p=0.024; b, TGF- $\beta$ 1 concentration, in compare rs2118181 GG and AA genotypes, p=0.094; c, TGF- $\beta$ 1 concentration, in compare rs10519177 AA and GG genotypes, p<0.0001;(rs2118181, rs10519177) and d, TGF- $\beta$ 1 concentration, in compare rs10519177 AG and GG genotypes, p<0.0001;TGF $\beta$ 1 Concentration in Human Plasma. " *Molecular Medicine* 21.1 (2015): 735.

#### Multiple linear regression for different modells of *FBN1* rs2118181 and rs10519177

FBN1 SNP	Dependent	Unstandardised	p value	Adjusted
	variables	Coefficients B		R²
rs2118181	Constant	1.045	< 0.001	0.103
	Gender (male)	0.185	0.015	
	Age	0.012	< 0.001	
	Genotype AG+GG	0.222	0.008	
	Constant	1.035	< 0.001	0.102
	Gender (male)	0.181	0.018	
	Age	0.012	< 0.001	
	Allele G	0.172	0.010	
rs10519177	Constant	1.053	< 0.001	0.146
	Gender (male)	0.158	0.034	
	Age	0.011	< 0.001	
	Genotype GG	0.397	< 0.001	

Sepetiene et al. "Association between Fibrillin1 Polymorphisms (rs2118181, rs10519177) and Transforming Growth Factor β1 Concentration in Human Plasma." *Molecular Medicine* 21.1 (2015): 735. Elevation of TGF–β1 concentration with statistically confident mannier is effected by male gender, older age and rs2118181 G allele

When *FBN1* rs2118181 was replaced by rs10519177 in this modeling, TGF- $\beta$ 1 concentration with statistically confident mannier is effected by **male gender**, **older age and rs10519177 GG** genotype


### Conclusions

FBN1 SNP rs2118181 and rs10519177 may rise a risk for dissection of ascending aorta, with OR 2.59 (CI 1.67-4.01), OR2.13 (1.48-3.08), respectively



*FBN1* SNP rs10519177 rises a risk for aneurysms of ascending aorta formation, with **OR 1.67 (CI 1.61-2.40)** 

*FBN1* SNP rs2118181 minor alelle or a pair of minor alleles for rs1059177 elevate the **TGF- β1** concentration in blood plasma, but the mechanism of this correlation is still unknown



A Genotype determination of FBN1 SNPs rs2118181 rs10519177 and detection of TGF- **β1 concentration** in blood plasma may be the potential biomarkers in clinical practice, for early diagnostics establish a risk for DPAA formation, to avoid a development of complications.

intern atul Repair ot a Gian e Bakey IIIB Dissectio ch, A Clinical Case Matures A Konto II Iver Matures A Konto II Iver Matures A Konto II Iver	The Importance of Fibrin in the Development of Sur of Aneurysms of the Aorti		Association betwee Transforming	e	research artic Blood PI Sporadic	European Journal of Cardio-Thoracic Surgery European Journal of Cardio-Thoracic Surgery (2015) 1-7 doi:10.1093/ejctu/exu520 Cite this article as: Lessuskalle V, Septiere R, Jatiene G, Patamogre V, Zakous G, pathology of the ascending thoracic aorta. Eur J Cardiothons: Surg 2015; doi:10.10 FBN1 polymorphisms in patient of the ascending	ORIGINAL AF rabussiyee I et al. 781/1 polymorphisms in patients with the dilatative 93/njctu/eus520.
its serveryone, messar's in advant 20% we pare (2), density year development of advancement of a server and the server and the server and the server and the server advancement of the server advance	C. Н∪тн <i>Abstract</i> The history of surgical treatment of aor hand, that therapeutic concepts have bee	The operative mortality rat	Ramune Sepetiene <sup>1</sup> Stanioniene <sup>1</sup> , Rima	a	Aorta: N Ramune Sepetie Zita Stanioniene I Institute of Cardio Gaunas, Lithuania, Sciences, Eiveniu 2 sepetiene@yaho	Vaiva Lesauskaite**, Ramune Sepetiene*, Geider Ingrida Grabauskyte*, Zita Stanioniene*, Rai * Institute of Cardiology of the Medical Academy, Lithuanian University of Health Sa * Institute of Cardio. Thoracc and Vacadar Sargery, Lithuanian University of H * Hear Sargery, Circlen, Vinta University Foodard Saramabian University of H * Corresponding author. Head of Laboratory of Medicular Cardiology, Ulthuanian University fet 3: 373-37205 (fas: 373-373-32735; e-mit) avail-assaratiset@Brunninu IIX (N Received 4 September 2014; received in revised form 28 November 2014; accepted Abstract	mondas Sirmenis' and Rimantas Benetis'' ierces, Kaunas, Lithuania alth Sciences, Kaunas, Lithuania ani viersity of Health Sciences, A. Mickewäaus 9, LT-44307 Kaunas, Lithuan Lesussiaite).
sime disection to the weight and the relation of the least instrumentation of the least of the least instrumentation of the least of the least instrumentation of the least the least instrumentation of the least the least instrumentation of the least and of the least instrumentation of the least in the least of the least instrumentation of the least of the least instrumentation of the least of	they could be realized clinically, and, on ally still important in addition to mod- ment of the aortic root is the last techn dures. It is followed only by an improve Fibrin glue (Tissucol Duo S, human fibr and gelatine-resorcine-formol glue (GR with aneurysms of the ascending aorta w 1992 in Tubingen and Bad Nauheim der cepts. Besides several variations in supr aorta, composite graft replacement has since more than 50% of patients under taneously received aortic valve replacen porosity prostheses and suture lines h GRF glue since 1989 for gluing dissectio	aneuryams was 31.5 per cent. KEY WORDS: aortic aneurys rysm, dissecting aneurysm, grad temporary external bypass. Iw Due to improved techniques in cardior aneurysms has made remarkable progres aneurysms no longer presents serious ri especially the ascending aorta or aortic a In 1973, Sunada <sup>15</sup> published a colle 915 cases of abdominal aneurysms noomp	<sup>1</sup> Institute of Cardiology o Sukileliu 17, Kaunas, Litt <sup>2</sup> Department of Cardiac, Sciences; Eiveniu 2, Kau	CONSTANT     CONSTANT	Abstract Fransforming gr sellular regulato ysm. Increased FBV1 mutations \$2 patients with and in reference dentified TGF- p Patients with DP ects (median 7. y). There is a sig	OBJECTIVES: To investigate polymorphisms of the fibrillin-1 (FBN1) rs4774517) in a case-control study for dilatative pathology of the ascen METHODS: We studied 312 patients who had undergone aortic re according to the phenotypes of their DPATA into (i) ascending aortic a due to aortic valve stenois (n=79) and (iii) Stanford A dissection (n sample screened within epidemiological studies of the Lithuanian po ase-chain-reaction amplification. RESULTS: Patients within the aortic dissection sub-group had significar polymorphism (SNN) studied versus reference group subjects (P < 0, d) significantly higher in those with aortic aneurysm when compared wit studied were significantly associated with aortic aseurysm (PR 1) genotypes with each phenotype of DPAIA was assessed using logistic	ding thoracic aorta (DPATA) from Lithuanians. constructive surgery for DPATA. These patients were sub- neuryam (n = 160, in) poot-stenotic cilitation of the ascendir = 73). The reference group (n = 472) was recruited from a pulation. FBN1 polymorphisms were studied by real-time p utily higher minor allele frequencies in all five FBN1 single nu 001). Minor allele frequencies in SNPs rs2118181, rs10364 th the reference group (P = 0.007). Thus, minor alleles of FBN signation control studies dispersion of the signature of the signature S7, confidence interval (CI) 95% 1.61–2.40]. The association of regression models adjusted for geneder, age and hypertensi
(100.2000 publication pairs yanta. Then cities a statistic to the intermediate of a config with the pairs begin to the statistical of the configuration and the statistical of the configuration of the statistical of the statistical of the configuration of the configuration of the statistical of the configuration of the statistical of the configuration of the statistical of the statistical of the configuration of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistical of the statistic	with composite graft replacement and fi diminished postoperative blood loss of 7 The considerably higher early mortality ronary replacement of the ascending a problems occurring in the proximal an ary replacement of the ascending aorta the average 3.5 years after the first ope the indication for composite graft repla mended in most cases of aneurysms of tive disease affects the entire root of undergoing supracoronary replacemen	that the operative mortality rate for tho and 16 per cent, respectively. From January, 1959, through June, of abdominal aneurysm underwent surgi hospitals. The over-all mortality rate 24.7 per cent and 9.3 per cent, respectiv This report presents our experience	Keywords: Ascending ao Corresponding author:	Routimestern Med CV, UNITED STATES     Revelved: January 6, 2015     Accepted: May 7, 2015     Published: June 23, 2015     Copyright: 6 2015 Sequeliane et al. This is an open     V	D 1.027–1.144, ished yet. Slight barison to the re disease. Howev among individua would also like to 31 levels with an	additive model best fitted SNPs rs2118181 and rs1056477 in associati 1.172-e36 or the Sanford A discriton sub-group (DR 264, Cl 958, L rs10519177, rs755251, rs7774517 and Stanford A dissection (DR 431, all studied FBN1 SNPs and post-senotic or bicuspid aortic dilatation. CONCLUSION: Cour study provide evidence for the following (P 17 may increase susceptibility to aortic dissections and (ii) FBN1 SNPs these SNPs might be considered as biomarkers for identifying patients Keywords: Thoracic aorta - Aneurysm - Dissection - Fibrillin-1 - Polymc	6–419, A recessive model fitted best the association betwee CI 95% 2.06–9.01. There were no significant associations b 9NI SNPs rs2118181, rs1036477, rs10519177, rs47745174, rs118181, rs1036477 to the formation of aortic answing at risk for ascending aortic aneurysm and aortic dissection.
n n genetik (de	even AVR. Supracoronary replacement even AVR. Supracoronary replacement by a high reoperation rate for secondar rysms of the aortic root. Early mortality ment of the aortic root is even lower t replacement of the ascending aorta. S GRF reduce postoperative blood loss a G. Schlag et al. (eds.), <i>Fibrin Scaling in Surgical</i> © Springer-Veng Berlin Heidelberg 1995	Japanese Journal of Surgery, Vol. 8, No.	Ramune Sepetiene Sukileliu 17, Kaunas, Litt +370 612 31784	credited. Data Availability Statement: All data are included within the manuscript. Funding: Funding was provided by the Research Council of Unavaira for National Research t	ntroduction Marfan syndrom seen discovered t TGF-β1) [ <u>1</u> ]. Th	INTRODUCTION The aetiology and pathogenesis of dilatative pathology within the ascending thoracic aorta (DPATA) remain under discussion. In most cases, the causes leading to such pathology of the aortic wall remain undear. Only in certain cases is the condition caused by aortifis, atheroacterosis or inherited as a single gene mutation. In these cases, the mutations are in the fibrillin (FRV) gens (eg. Marfan syndrome) [12 is inherited collagen mutations (eg. Eher- Danlos syndrome) [12 is mutations of the transforming growth	factor-beta gene causing Loeys-Dietz syndrome [3] or 1 gene mutations [4] Evidence has shown that FRN1 mutation predispose one to DPAIA in the absence of phenotypic ch istics of Marfan syndrome [5, 6], Recently, published data fi genome-wide association study (OWAS) identified novel- tions of FRN1 SNPs at chromosome 15q21.1: namely, rs1 rs2118181, rs10519177, rs4774517, rs755251, with sporadic [7]. These data settend knowledge of the molecular p leading to sporadic thoracic disease, and may connect it model of Marfan syndrome.

#### References

- Lesauskaite, Vaiva, et al. FBN1 polymorphisms in patients with the dilatative pathology of the ascending thoracic aorta, 2015, *European Journal of Cardio-Thoracic Surgery*: ezu520
- Allaire E et al, New insight in aethiopathogenesis of aortic diseases, 2009, Eur J Vasc Endovasc Surg 37, 531-537
- Kaartinen V, Warburton D, Fibrillin controls TGF-β activation, 2003, Nat Genet 33, 644-647
- Jones J A et al, Transforming Growth Factor- β signaling in thoracic aortic aneurysm development: a paradox in Pathogenesis, 2009, J Vasc Research 46, 119-137
- Pannu H et al, Genetic basis of thoracic aortic aneurysms and aortic disection, 2005, American J Med Genet 139, 10-16
- Toma I et al, Transforming growth factor- β and atherosclerosis: interwoven atherogenic and atheroprotective aspects, 2012, Cell Tissue Res 347, 155-175
- Pardali E et al, Signaling by members of the TGF- β family in vascular morphogenesis and disease, 2010, Trends in cell Biol 20, 556-567
- Lesauskaite V, Dilatative pathology of ascending aorta, a new attitude, Oral presentation , 2012.

## Thank you!



From "Manga Guide to Statistics", Shin Takahashi, 2008

#### Thank's to our team for the all hard work!





Head of Laboratory of Molecular Cardiology, Prof. habil. dr. Vaiva Lesauskaite



Prof. habil.dr. Jolanta Justina Vaskelyte



Prof. habil.dr. Rimantas Benetis



Prof. habil.dr. Abdonas Tamosiunas



PhD student, MD Giedrius Zukovas



PhD student Vaiva Patamsyte



Dr. Giedre Jariene



Dr. Giedre Marsalkiene